Can-Fite Secures Japanese Patent for Obesity Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Source: stocktwits
- Patent Approval: Can-Fite has secured a patent in Japan for its lead drug candidate Namodenoson, which covers its use for fat loss and the treatment of obesity and related metabolic disorders, thereby strengthening the company's intellectual property portfolio, which already includes protections in the U.S., Canada, and Australia.
- Clinical Trial Progress: Namodenoson is currently undergoing a Phase 3 trial for advanced liver cancer and a Phase 2b study for metabolic dysfunction-associated steatohepatitis, demonstrating its potential across various metabolic diseases, particularly in obesity treatment.
- Positive Market Reaction: Following the patent news, Can-Fite's shares surged over 10% in early trading on Friday, although some gains were later pared, indicating investor optimism regarding the company's future market performance and product potential.
- Investor Sentiment Shift: According to Stocktwits, investor sentiment for Can-Fite shifted from 'bullish' to 'extremely bullish', reflecting heightened expectations for upcoming clinical trial results, especially for the Phase 3 trial evaluating Piclidenoson for psoriasis, with interim results anticipated in Q2 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CANF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CANF
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Can-Fite Secures Japanese Patent Enhancing Market Position
- Patent Protection Strengthened: Can-Fite BioPharma has secured a patent in Japan for its lead drug candidate Namodenoson, further solidifying its intellectual property in the global obesity and metabolic disease treatment space, showcasing the company's competitive edge in the market.
- Significant Market Potential: The global obesity therapeutics market is projected to exceed $60 billion by 2030, with Can-Fite's Namodenoson offering a differentiated oral treatment option that meets the growing demand for safe, effective, and convenient therapies.
- Scientific Validation Support: Recent studies published in the International Journal of Obesity have confirmed Namodenoson's anti-obesity activity, providing independent scientific validation for its novel mechanism of action, thereby enhancing its market appeal.
- Clinical Trial Progress: Namodenoson is currently undergoing a pivotal Phase 3 trial for hepatocellular carcinoma and has shown promising results in pancreatic cancer and metabolic dysfunction-associated steatohepatitis, bolstering its potential as a future obesity therapy candidate.
See More
Can-Fite Secures Japanese Patent for Obesity Treatment
- Patent Approval: Can-Fite has secured a patent in Japan for its lead drug candidate Namodenoson, which covers its use for fat loss and the treatment of obesity and related metabolic disorders, thereby strengthening the company's intellectual property portfolio, which already includes protections in the U.S., Canada, and Australia.
- Clinical Trial Progress: Namodenoson is currently undergoing a Phase 3 trial for advanced liver cancer and a Phase 2b study for metabolic dysfunction-associated steatohepatitis, demonstrating its potential across various metabolic diseases, particularly in obesity treatment.
- Positive Market Reaction: Following the patent news, Can-Fite's shares surged over 10% in early trading on Friday, although some gains were later pared, indicating investor optimism regarding the company's future market performance and product potential.
- Investor Sentiment Shift: According to Stocktwits, investor sentiment for Can-Fite shifted from 'bullish' to 'extremely bullish', reflecting heightened expectations for upcoming clinical trial results, especially for the Phase 3 trial evaluating Piclidenoson for psoriasis, with interim results anticipated in Q2 2026.
See More
Can-Fite BioPharma to Attend BIO International Convention
- Clinical Trial Progress: Can-Fite's lead drug candidate, Namodenoson, is currently undergoing a pivotal Phase III study for advanced hepatocellular carcinoma while completing a Phase IIa study in pancreatic cancer, indicating its potential in oncology and possibly opening new market opportunities for the company.
- New Drug Development: Piclidenoson, aimed at inflammatory diseases, is in a pivotal Phase III study for psoriasis and preparing for a Phase II study in the rare genetic disease Lowe Syndrome, further enriching the company's product pipeline.
- Strategic Partnership Opportunities: At the 2026 BIO International Convention, Can-Fite will hold partnering meetings with pharmaceutical and biotech companies to discuss licensing and commercialization opportunities for its clinical-stage pipeline, which is expected to generate new revenue streams for the company.
- Market Potential Assessment: Can-Fite's A3 adenosine receptor platform technology has demonstrated a favorable safety profile in over 1,600 patients, and with approximately $20 million in licensing agreement revenues generated globally, it highlights the significant market potential in cancer and inflammatory disease treatments.
See More
Can-Fite BioPharma Publishes Canine Osteoarthritis Study Results
- Publication of Findings: Can-Fite BioPharma published a study in the journal Frontiers in Veterinary Science regarding Piclidenoson's efficacy in treating canine osteoarthritis, demonstrating significant improvements in mobility and pain assessments at a dosage of 500 µg/kg BID, indicating its potential as an oral disease-modifying therapy.
- Clinical Data Validation: The study reported significant enhancements in Liverpool Osteoarthritis scores and reductions in pain as measured by the Visual Analog Scale (VAS), with no serious treatment-related adverse events, confirming the drug's favorable safety profile.
- Market Opportunity: Canine osteoarthritis is a prevalent chronic condition among dogs, with limited current treatment options; the development of Piclidenoson not only addresses this unmet need but also presents a potential revenue opportunity of up to $325 million from Can-Fite's collaboration with Vetbiolix.
- Strategic Collaboration Outlook: The Chief Scientific Officer of Can-Fite noted that the publication of these findings provides important external validation of Piclidenoson's therapeutic potential, further supporting the commercial prospects of their partnership with Vetbiolix, which is expected to drive growth in the veterinary market.
See More
Can-Fite BioPharma Reports Positive Clinical Data for Namodenoson
- Clinical Trial Results: Can-Fite's Phase 2a study for advanced pancreatic cancer shows over 30% of evaluable patients with stable disease, indicating potential clinical activity in a heavily pretreated population, which may provide durable treatment benefits for this difficult-to-treat group.
- Treatment Duration: Some patients in the study have been treated for over 16 months, with 35% remaining on therapy, reflecting not only the drug's good tolerability but also supporting the clinical necessity for continued development of namodenoson.
- Safety Analysis: The primary objective of the study was to assess the safety profile of namodenoson, which was found to be consistent with previous reports, with no new safety signals identified, further enhancing its potential application in other oncological diseases.
- Future Outlook: Can-Fite expects to release comprehensive efficacy analysis results, including progression-free survival and overall survival, in the coming months, which will provide crucial data support for the clinical development of namodenoson in pancreatic cancer.
See More
Can-Fite Signs Up to $325M Deal with Vetbiolix
- Clinical Trial Progress: Vetbiolix has completed enrollment of 118 dogs in the Phase 2 clinical trial of Piclidenoson, with top-line results expected in Q3 2026, which could significantly boost Can-Fite's revenue in the veterinary market if successful.
- Market Potential: The global canine osteoarthritis market is projected to reach approximately $3 billion by 2028, and Can-Fite's Piclidenoson is poised to become a safe and effective treatment option, addressing the growing demand for pet healthcare.
- Agreement Details: Under the agreement, Can-Fite is entitled to receive up to $325 million in upfront, milestone, and royalty payments, with Vetbiolix responsible for all development and regulatory activities, highlighting the depth and potential of their collaboration.
- Product Background: Piclidenoson is a novel A3 adenosine receptor agonist that has demonstrated excellent safety and efficacy in a Phase III trial for psoriasis, and it is expected to play a significant role in treating canine osteoarthritis in the future.
See More
Can-Fite Secures Japanese Patent Enhancing Market Position
- Patent Protection Strengthened: Can-Fite BioPharma has secured a patent in Japan for its lead drug candidate Namodenoson, further solidifying its intellectual property in the global obesity and metabolic disease treatment space, showcasing the company's competitive edge in the market.
- Significant Market Potential: The global obesity therapeutics market is projected to exceed $60 billion by 2030, with Can-Fite's Namodenoson offering a differentiated oral treatment option that meets the growing demand for safe, effective, and convenient therapies.
- Scientific Validation Support: Recent studies published in the International Journal of Obesity have confirmed Namodenoson's anti-obesity activity, providing independent scientific validation for its novel mechanism of action, thereby enhancing its market appeal.
- Clinical Trial Progress: Namodenoson is currently undergoing a pivotal Phase 3 trial for hepatocellular carcinoma and has shown promising results in pancreatic cancer and metabolic dysfunction-associated steatohepatitis, bolstering its potential as a future obesity therapy candidate.
See More
Can-Fite Secures Japanese Patent for Obesity Treatment
- Patent Approval: Can-Fite has secured a patent in Japan for its lead drug candidate Namodenoson, which covers its use for fat loss and the treatment of obesity and related metabolic disorders, thereby strengthening the company's intellectual property portfolio, which already includes protections in the U.S., Canada, and Australia.
- Clinical Trial Progress: Namodenoson is currently undergoing a Phase 3 trial for advanced liver cancer and a Phase 2b study for metabolic dysfunction-associated steatohepatitis, demonstrating its potential across various metabolic diseases, particularly in obesity treatment.
- Positive Market Reaction: Following the patent news, Can-Fite's shares surged over 10% in early trading on Friday, although some gains were later pared, indicating investor optimism regarding the company's future market performance and product potential.
- Investor Sentiment Shift: According to Stocktwits, investor sentiment for Can-Fite shifted from 'bullish' to 'extremely bullish', reflecting heightened expectations for upcoming clinical trial results, especially for the Phase 3 trial evaluating Piclidenoson for psoriasis, with interim results anticipated in Q2 2026.
See More
Can-Fite BioPharma to Attend BIO International Convention
- Clinical Trial Progress: Can-Fite's lead drug candidate, Namodenoson, is currently undergoing a pivotal Phase III study for advanced hepatocellular carcinoma while completing a Phase IIa study in pancreatic cancer, indicating its potential in oncology and possibly opening new market opportunities for the company.
- New Drug Development: Piclidenoson, aimed at inflammatory diseases, is in a pivotal Phase III study for psoriasis and preparing for a Phase II study in the rare genetic disease Lowe Syndrome, further enriching the company's product pipeline.
- Strategic Partnership Opportunities: At the 2026 BIO International Convention, Can-Fite will hold partnering meetings with pharmaceutical and biotech companies to discuss licensing and commercialization opportunities for its clinical-stage pipeline, which is expected to generate new revenue streams for the company.
- Market Potential Assessment: Can-Fite's A3 adenosine receptor platform technology has demonstrated a favorable safety profile in over 1,600 patients, and with approximately $20 million in licensing agreement revenues generated globally, it highlights the significant market potential in cancer and inflammatory disease treatments.
See More
Can-Fite BioPharma Publishes Canine Osteoarthritis Study Results
- Publication of Findings: Can-Fite BioPharma published a study in the journal Frontiers in Veterinary Science regarding Piclidenoson's efficacy in treating canine osteoarthritis, demonstrating significant improvements in mobility and pain assessments at a dosage of 500 µg/kg BID, indicating its potential as an oral disease-modifying therapy.
- Clinical Data Validation: The study reported significant enhancements in Liverpool Osteoarthritis scores and reductions in pain as measured by the Visual Analog Scale (VAS), with no serious treatment-related adverse events, confirming the drug's favorable safety profile.
- Market Opportunity: Canine osteoarthritis is a prevalent chronic condition among dogs, with limited current treatment options; the development of Piclidenoson not only addresses this unmet need but also presents a potential revenue opportunity of up to $325 million from Can-Fite's collaboration with Vetbiolix.
- Strategic Collaboration Outlook: The Chief Scientific Officer of Can-Fite noted that the publication of these findings provides important external validation of Piclidenoson's therapeutic potential, further supporting the commercial prospects of their partnership with Vetbiolix, which is expected to drive growth in the veterinary market.
See More
Can-Fite BioPharma Reports Positive Clinical Data for Namodenoson
- Clinical Trial Results: Can-Fite's Phase 2a study for advanced pancreatic cancer shows over 30% of evaluable patients with stable disease, indicating potential clinical activity in a heavily pretreated population, which may provide durable treatment benefits for this difficult-to-treat group.
- Treatment Duration: Some patients in the study have been treated for over 16 months, with 35% remaining on therapy, reflecting not only the drug's good tolerability but also supporting the clinical necessity for continued development of namodenoson.
- Safety Analysis: The primary objective of the study was to assess the safety profile of namodenoson, which was found to be consistent with previous reports, with no new safety signals identified, further enhancing its potential application in other oncological diseases.
- Future Outlook: Can-Fite expects to release comprehensive efficacy analysis results, including progression-free survival and overall survival, in the coming months, which will provide crucial data support for the clinical development of namodenoson in pancreatic cancer.
See More
Can-Fite Signs Up to $325M Deal with Vetbiolix
- Clinical Trial Progress: Vetbiolix has completed enrollment of 118 dogs in the Phase 2 clinical trial of Piclidenoson, with top-line results expected in Q3 2026, which could significantly boost Can-Fite's revenue in the veterinary market if successful.
- Market Potential: The global canine osteoarthritis market is projected to reach approximately $3 billion by 2028, and Can-Fite's Piclidenoson is poised to become a safe and effective treatment option, addressing the growing demand for pet healthcare.
- Agreement Details: Under the agreement, Can-Fite is entitled to receive up to $325 million in upfront, milestone, and royalty payments, with Vetbiolix responsible for all development and regulatory activities, highlighting the depth and potential of their collaboration.
- Product Background: Piclidenoson is a novel A3 adenosine receptor agonist that has demonstrated excellent safety and efficacy in a Phase III trial for psoriasis, and it is expected to play a significant role in treating canine osteoarthritis in the future.
See More
